@article {243,
	title = {Drug Review: Eflapegrastim},
	journal = {PTB Reports},
	volume = {9},
	year = {2023},
	month = {November 2023},
	pages = {52-53},
	type = {Drug Review},
	chapter = {52},
	abstract = {<p class="rtejustify">Registrations: It had been registered in the following countries United States of America (USA), United Kingdom (U.K.), Canada, and Saudi Arabia (S.A.) Trade name (USA); ROLVEDON Registration number (S.A.); Not Available. Insurance Drug Formulary (S.A.); Not covered (29.1.2023). General Information: Registered Company: Spectrum Pharmaceuticals. Regulatory Status: R.X. Mechanism of Action: A recombinant human granulocyte growth factor activates signaling pathways that affect cell differentiation, proliferation, migration, and survival by binding to G-CSF receptors on myeloid progenitor cells and neutrophils.\&nbsp;<strong> Read more...</strong></p>
},
	doi = {10.5530/PTB.2023.9.8},
	author = {Juman Alsaab}
}
